Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22964772 | 0.82 | CHEK1 (0.47) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL13064189 | 0.82 | CHEK1 (0.47) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL14262877 | 0.81 | CHEK1 (0.34) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL20609561 | 0.80 | CHEK1 (0.45) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL14262869 | 0.74 | CHEK1 (0.31) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL8018832 | 0.74 | CHEK1 (0.59) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL15627224 | 0.72 | MAPK1 (0.49) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL10139174 | 0.72 | ADORA2A (0.36) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL2843606 | 0.71 | CHEK1 (0.61) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL10295523 | 0.71 | CHEK1 (0.41) | CHEK1AURKADAPK3JAK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-11021467-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-06-01 | — | — | US | disclosed |
| US-20210040080-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| WO-2020185593-A1 | AZETIDINYL 0-GLYC0PR0TEIN-2-ACETAMID0-2-DEOXY-3-D-GLUC0PYRAN0SIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CHEK1 1367/4885AURKA 2507/4885DAPK3 1666/4885 |
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST3GAL3, ST6GAL1 | CHEK1 4286/4885AURKA 4073/4885DAPK3 3208/4885 |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | CHEK1 4823/4885AURKA 3451/4885DAPK3 3189/4885 |
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT2 | CHEK1 323/4885AURKA 344/4885DAPK3 489/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CHEK1 1367/4885AURKA 2507/4885DAPK3 1666/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | CHEK1 4823/4885AURKA 3451/4885DAPK3 3189/4885 |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | ATG7, MLST8, BECN1 | CHEK1 4264/4885AURKA 2274/4885DAPK3 720/4885 |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | ATG7, MLST8, BECN1 | CHEK1 4385/4885AURKA 2709/4885DAPK3 729/4885 |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | CHEK1 708/4885AURKA 1191/4885DAPK3 2961/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | CHEK1 260/4885AURKA 1399/4885DAPK3 2043/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | CHEK1 2329/4885AURKA 3994/4885DAPK3 1884/4885 |
| US-20210040080-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST6GAL1, ST3GAL3 | CHEK1 4299/4885AURKA 4215/4885DAPK3 3432/4885 |
| US-11021467-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, PIK3C2B, PIK3CB | CHEK1 328/4885AURKA 294/4885DAPK3 564/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | CHEK1 1273/4885AURKA 1089/4885DAPK3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.